immune protection
[대역어] None
[용어속성] Term
[용어속성] Term
A hybrid discrete-continuum model of immune responses to SARS-CoV-2 infection in the lung alveolar region, with a focus on interferon induced innate response
Article
[키워드] adaptive
alveolar
alveolar cells
antibodies
antibody
antibody concentration
baseline
Cell
cell death
Cellular automaton
COVID-19
develop
diffusion
domain
Efficacy
Future
Gas exchange
healthy
human lung
Immune cell
immune protection
immune response
Immunity
infected cell
Infection
initial
Innate
innate immune
Innate immunity
innate response
Interaction
interferon
interferons
lung alveolar
maintain
manuscript
mechanism
Model
multiple mechanism
outcome
Pneumonia
produced
profiles
progression
Result
RNA copy
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 variant
simulations.
Spread
Strains
submitted
switching
T cells
the SARS-CoV-2 virus
two-dimensional
type I
Viral load
virion
virions
[DOI] 10.1016/j.jtbi.2022.111293 PMC 바로가기
[DOI] 10.1016/j.jtbi.2022.111293 PMC 바로가기
A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunity
COVID-19 회복기에 대한 1년 종단 연구는 항 SARS-CoV-2 체액성 및 세포성 면역의 지속성을 보여줍니다
Article
[키워드] 1-year after infection
anti-SARS-CoV-2 humoral
antibody
antibody durability.
caused
CD4
CD8
CD8 T cell
CD8 T cell responses
Cell
cellular immunity
central memory
circulating antibodies
circulating antibody
Cohort
convalescent
COVID-19
COVID-19 convalescent
COVID-19 patient
disease
disease severity
effective
IgG level
immune
Immune components
immune memory
immune protection
Immunity
induce
Infection
information
Kinetics
maintain
memory
memory B
memory B cell
Memory responses
memory T cells
omicron
Omicron variant
peptide
peptide pool
persistence
protective immunity
provide
RBD IgG
Re-infection
recorded
response
reveal
SARS-CoV-2
SARS-CoV-2 circulating antibodies
SARS-COV-2 infection
subject
Symptom
T cell
T cell response
T cell responses
T cells
tested
the RBD
the SARS-CoV-2
variant
[DOI] 10.1080/22221751.2022.2049984 PMC 바로가기 [Article Type] Article
[DOI] 10.1080/22221751.2022.2049984 PMC 바로가기 [Article Type] Article
Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain
SARS-CoV-2 S2 도메인에 대한 항체의 결합 및 중화 능력
Article
Published on
Journal: Human vaccines & immunotherapeutics
[Category] COVID19(2023년), MERS, SARS, 변종, 진단,
Journal: Human vaccines & immunotherapeutics
[Category] COVID19(2023년), MERS, SARS, 변종, 진단,
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
antibodies
antibody
B.1.1.7
B.1.351
B.1.617.2
B.1.621
binding
binding activity
carried
conserved
convalescent patient
coronavirus
coronavirus 2
coronavirus disease
Coronavirus disease 2019
COVID-19
determined by
domain
ELISA
enzyme
enzyme-linked immunosorbent
enzyme-linked immunosorbent assay
evaluated
Evidence
Immune escape
immune protection
mAb
mAbs
MERS
MERS-CoV
Middle East
Middle East respiratory syndrome
Middle East respiratory syndrome Coronavirus
molecular
monoclonal antibodies
monoclonal antibody
N Terminal
N terminal domain
NAbs
Neutralization assay
neutralization assay.
Neutralizing
Neutralizing activity
Neutralizing antibodies
neutralizing antibody
NTD
P.1
Protein
pseudo-virus
RBD
Receptor binding domain
reported
Research
respiratory
Result
S protein
S proteins
S2 protein
S2 subunit
SARS-CoV
SARS-CoV-2
SARS-CoV-2 RBD
SARS-CoV-2 S
SARS-CoV-2 S2
SARS-CoV-2 WT
Severe acute respiratory syndrome
severe acute respiratory syndrome Coronavirus
significantly
specific antibodies
subunit
target
targets
terminal
Vaccine design
variant
variants
wild-type
[DOI] 10.1080/21645515.2022.2055373 PMC 바로가기 [Article Type] Article
[DOI] 10.1080/21645515.2022.2055373 PMC 바로가기 [Article Type] Article
SARS-CoV-2 Infection Causes Hyperglycemia in Cats
Article
[키워드] ACE2
acute respiratory syndrome
blood glucose
cats
cause
Cell
cells
conducted
contribute
coronavirus
coronavirus disease
COVID-19
diabete
diabetes
dysregulation
Endocrine
Ex vivo
exhibited
experiment
experimental evidence
expressed
High dose
hyperglycemia
immune protection
immunized
in vivo
infect
Infection
islet
Isolated
lack
pancrea
pancreas
pancreatic
Patient
Protein
Research
researcher
SARS-CoV-2
SARS-CoV-2 nucleocapsid
SARS-CoV-2 RNA
Spike protein
staining
tissue
viruses
viruses.
[DOI] 10.1093/infdis/jiac143 PMC 바로가기
[DOI] 10.1093/infdis/jiac143 PMC 바로가기
Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination
Article
[키워드] acute respiratory syndrome
analyzed
antibody
CD4
CD4+
CD4+ T cells
CD8
CD8+
CD8+ T cells
Cellular immune response
competent
coronavirus
COVID-19
COVID-19 vaccination
develop
dose
elicited
ELISPOT
exhibited
had no
healthy individuals
humoral
ICU
immune protection
immune response
individual
individuals
information
intensive care
intensive care unit workers
lack
maintain
mRNA
mRNA COVID-19 vaccines
mRNA vaccine
neutralizing antibody
proportion
Protein
protein S
reactive
receiving
reduction in
SARS-CoV-2
SARS-CoV-2-specific T cell
Seroconversion
seronegative
Specific T-cell response
susceptibility
T cell
T cell response
T cells
T lymphocyte
T-cell
the S protein
the SARS-CoV-2
the spike protein
vaccination
vaccination.
viral infection
Viral protein
[DOI] 10.3389/fimmu.2022.942192 PMC 바로가기
[DOI] 10.3389/fimmu.2022.942192 PMC 바로가기
Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients
Article
[키워드] ACE2 binding
addition
administration
analysed
anti-RBD
B.1
binding
BNT162b2
boost immunity
cellular
Control
controls
COVID-19
COVID-19 vaccination
Decline
declining
Delta
detectable
dialysis
dose
doses
group
Haemodialysis
Haemodialysis patient
humoral
humoral immune response
Humoral immunity
IgG
IgG response
immune
immune evasion
immune protection
immunoassays
Immunocompromised
individual
individuals
information
interferon γ
knowledge
longitudinal
longitudinal response
maintain
mixed mRNA vaccination
mRNA
mRNA vaccination
mRNA-1273
mucosal
omicron
Omicron variant of concern
Patient
patients
Prevent
protective immunity
protective immunity.
RBD
reached
regimen
remained
respond poorly
restored
SARS-CoV-2 vaccination
SARS-CoV-2 variant
second vaccination
severe COVID-19
significantly increased
spike
subsequent
Support
T-cell Response
tested
the receptor-binding domain
vaccination
Vaccine
variant
variants of concern
[DOI] 10.3389/fimmu.2022.1004045 PMC 바로가기
[DOI] 10.3389/fimmu.2022.1004045 PMC 바로가기
Technology-assisted adaptive recruitment strategy for a large nation-wide COVID-19 vaccine immunogenicity study in Brunei
Article
[키워드] adaptive
adaptive recruitment
Administered
age
analysed
antibody
AZD1222
BBIBP-CorV
behavioural
Brunei
circumvent
conducted
Contact
Contact tracing
Coverage
COVID-19
COVID-19 vaccine
Data integration
Digital
digital technology
dose
Electronic health records
electronic medical records
eligible
enrolled
example
Gender
immune protection
IMPROVE
include
individual
information
Intervention
limitation
Local
media
Mobile health
MOST
National
neutralising antibodies (NAB).
neutralising antibody
outcome
participant
platform
press
random
real time
recruit
recruitment
Research
SARS-CoV-2
SMS
stratified
Study participants
survey platform
technology
time-consuming
Vaccine
Vaccines
[DOI] 10.3389/fpubh.2022.983571 PMC 바로가기
[DOI] 10.3389/fpubh.2022.983571 PMC 바로가기
Single-cell analysis of the adaptive immune response to SARS-CoV-2 infection and vaccination
Article
[키워드] adaptive
Adaptive immune response
adaptive immune responses
addition
antibody
antibody production
B cells
B-cell
BCR
component
COVID-19
Critical
develop
effective
flow cytometry
immune
immune protection
immune response
Infection
Measures
molecular mechanism
natural infection
offer
pandemic
Pathogenesis
Protective
recent
receptor
SARS-CoV-2
SARS-COV-2 infection
severity
single-cell
single-cell analysis
single-cell analysis
Support
T cell
T-cell receptor
TCR
the disease
therapeutic intervention
transcriptomics
vaccination
Vaccine
vaccine.
variants
[DOI] 10.3389/fimmu.2022.964976 PMC 바로가기
[DOI] 10.3389/fimmu.2022.964976 PMC 바로가기
Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses
Article
[키워드] administration
allogeneic HSCT
Anti-spike
antibody
Antibody Response
Beta
BNT162b2 vaccine
booster
Breakthrough infection
can be used
circulation
correlated
COVID-19
COVID-19 vaccine
Delta
delta variant
dose
enzyme
France
healthy
hematopoietic
high-risk population
HSCT
HSCT immunocompromised patients
HSCT recipient
humoral
Humoral response
immune
immune protection
Immune suppression
immunoassay
Immunocompromised
immunocompromised individuals
Immunocompromised patients
Immunosuppressed
individual
marker
monoclonal antibody
Neutralization assay
neutralization titer
Neutralizing
Neutralizing activity
neutralizing antibody
Neutralizing antibody response
omicron
preventive measure
PROTECT
Protein
question
raised
recipient
recipients
response
SARS-CoV-2
SARS-CoV-2 variant
sensitivity
significantly lower
STEM
Strategy
Support
tested
the vaccine
Transplant
vaccination
vaccine dose
variant
Variant of concern.
variants
[DOI] 10.3390/v14091928 PMC 바로가기
[DOI] 10.3390/v14091928 PMC 바로가기